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Abstract
Objective: Mucosal healing (MH) is an important treatment goal in patients with inflammatory bowel disease (IBD), but
factors predicting MH under medical therapy are largely unknown. In this study, we aimed to characterize predictive factors
for MH in anti-TNF-alpha antibody-treated IBD patients.
Methods: We retrospectively analyzed 248 IBD patients (61.3% CD, 38.7% UC) treated with anti-TNF-alpha antibodies
(infliximab and/or adalimumab) for MH, defined as macroscopic absence of inflammatory lesions (Mayo endoscopy score 0
or SES-CD score 0) in colonoscopies which were analyzed before and after initiation of an anti-TNF-alpha antibody
treatment.
Results: In patients treated with only one anti-TNF-alpha antibody (‘‘TNF1 group’’, n = 202), 56 patients (27.7%) achieved
complete MH at follow-up colonoscopy (median overall follow-up time: 63 months). In a second cohort (n = 46), which
comprised patients who were consecutively treated with two anti-TNF-alpha antibodies (‘‘TNF2 group’’), 13 patients (28.3%)
achieved complete MH (median overall follow-up time: 64.5 months). Compared to patients without MH, CRP values at
follow-up colonoscopy were significantly lower in patients with MH (TNF1 group: p = 8.3561025; TNF2 group: p = 0.002).
Multivariate analyses confirmed CRP at follow-up colonoscopy as predictor for MH in the TNF1 group (p = 0.012). Overall
need for surgery was lower in patients with MH (TNF1 group: p = 0.01; TNF2 group: p = 0.03).
Conclusions: We identified low serum CRP level at follow-up colonoscopy as predictor for MH, while MH was an excellent
negative predictor for the need for surgery.
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Competing Interests: F. Beigel, F. Schnitzler, T. Ochsenkühn and S. Brand received lecture fees, travel support and financial support for research from: Abbott,
MSD. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
* Email: florian.beigel@med.uni-muenchen.de
" These authors share senior authorship on this work.
Introduction
Treatment of patients with inflammatory bowel disease (IBD)
has been focused but is also currently focused on symptomatic
relief and clinical improvement. However, since the course of IBD
may progress from an inflammatory to a stricturing and
penetrating type of disease with a high rate of bowel surgery (up
to 80% in Crohn’s disease (CD)) [1,2], early and sufficient
treatment strategies to protect the mucosal integrity and therefore
prevent disease progression are warranted. Colonoscopy is the
gold standard for diagnosing mucosal injury in IBD patients and to
evaluate the efficacy of therapy. Various endoscopic scores (e.g.
Mayo [3], Matts [4] and Lichtiger score [5] in ulcerative colitis;
CDEIS [6] or SES-CD [7] in CD) are used in clinical practice and
clinical studies to assess the mucosal status in IBD patients. Since
routine surveillance colonoscopy in asymptomatic IBD patients
without dysplastic lesions depending on the severity and type of
IBD are recommended only every 2–15 years, the mucosal status
after initiation or maintenance of a new therapy often remains
unclear in most of these patients. Moreover, willingness for control
colonoscopy in asymptomatic patients is low.
There is growing evidence, that mucosal healing (MH) is
associated with a better long-term outcome, lower need for
surgeries and hospitalisation and improved quality of life in IBD
patients [8,9,10]. Moreover, in a statement of the European
Crohn’s and Colitis Organization (ECCO) regarding the impact of
MH on the course of IBD, the need for further studies was
addressed [11].
Therefore, we aimed to analyze in this study the real-life
prevalence and predictive factors of mucosal healing in IBD
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This was a retrospective study using medical records, and
statistical analysis was anonymized. The ethics committee of the
University of Munich was consulted (UE number 055-13) and a
formal written waiver for the need of ethics approval was obtained.
Written informed consent of the patients was not obtained, since
patient records and relevant data were anonymized and de-
identified prior to analysis.
Study cohorts
All patients, who received anti-TNF-alpha antibody treatment
(infliximab or adalimumab) at our IBD center for the first time and
during the time period from 2002 to 2013, were eligible for this
study. Out of this cohort, patients with at least one colonoscopy
before start of (baseline colonoscopy) and one during anti-TNF-
alpha antibody treatment (follow-up colonoscopy) were included in
this study (Figure 1). If more than one baseline or follow-up
colonoscopy was available for analysis, the last colonoscopy before
start of anti-TNF-alpha antibody treatment and the first colonos-
copy after start of anti-TNF-alpha antibody treatment were used
for analysis, respectively. Patients, who were treated with a second
anti-TNF-alpha antibody after loss of response or intolerance to
the first anti-TNF-alpha antibody between the time periods from
baseline to follow-up colonoscopy, were assigned to the cohort
‘‘TNF2 group’’. All other patients were assigned to the cohort
‘‘TNF1 group’’. For further analyses, patients were divided
according their disease entities (CD group and UC group).
Medical records were analyzed regarding the following param-
eters: demographics, C-reactive protein (CRP) value at baseline
and follow-up colonoscopy, white blood cell count (WBC) at
baseline and follow-up colonoscopy, age at first diagnosis, disease
duration, type of anti-TNF-alpha antibody, concomitant medica-
tion, time to first anti-TNF-alpha antibody treatment, duration of
anti-TNF-alpha antibody treatment, time between baseline and
follow-up colonoscopy, smoking, BMI, extraintestinal manifesta-
tion, family history of IBD, reason for second (follow-up)
endoscopy and hospitalization or surgery from baseline colonos-
copy until last follow-up.
Medical treatment
Adalimumab was injected at doses of 160 mg loading dose,
following 80 mg and then 40 mg subcutaneously every other
week. Infliximab infusions were administered using a dose of
5 mg/kg body weight intravenously over 2 hours at weeks 0, 2, 6
(induction therapy) and thereafter every 8 weeks (maintenance
therapy). Thiopurines were given at the full dose (mercaptopurine
1.0–1.5 mg/kg body weight, azathioprine 2.0–2.5 mg/kg body
weight) from the beginning of therapy.
Endoscopy and histopathological analysis
Colonoscopy reports of baseline and follow-up colonoscopies
were analyzed by two independent medical reviewers. The Mayo
endoscopy score [3] was used for patients with UC and the SES-
CD score [7] for patients with CD. Patients with macroscopic
absence of IBD-defining markers and a Mayo endoscopy subscore
of 0 (UC) or a SES-CD score of 0 (CD) were defined as patients
with MH. All other patients were defined as patients without MH.
Statistical analysis
Comparison of demographic and clinical characteristics of the
study populations was performed using the x2-test or Fisher’s exact
test for categorical variables and by using the Wilcoxon-Mann-
Whitney test for continuous variables. Survival analyses techniques
were used to model the time to surgery. All statistical analyses were




Data of 802 IBD patients were available for analysis (Figure 1).
Out of these patients, 248 patients met the inclusion criteria and
were eligible for the study. 152 patients (61.3%) had CD and 96
(38.7%) had UC.
In the TNF1 group (n = 202), 120 patients (59.4%) had CD and
82 patients (40.6%) had UC. One hundred and eight patients were
female (52.5%); median of overall follow-up time for all patients
was 63 months (range 3–127 months).
The TNF2 group consisted of 46 patients, 32 (69.6%) with CD
and 14 (30.4%) with UC. Twenty patients were female (43.5%),
median of follow-up time for the patients of the TNF2 group was
64.5 months (range 9–126). The demographic and clinical
characteristics of the study cohorts are provided in table 1 and
tables S1 and S6 (UC/CD subcohorts).
In the TNF2 group, 42 patients were switched from infliximab
to adalimumab and 4 patients were switched from adalimumab to
infliximab. Reasons for the switch from a first anti-TNF-alpha
antibody to a second anti-TNF-alpha antibody in these patients
were allergic reactions (n = 30; 65.2%), intolerance (n = 3; 6.5%)
and loss of response (n = 13; 28.3%).
The most common reason for the second (follow-up) endoscopy
was routine control colonoscopy (174 patients = 86.1% in the
TNF1 group, and 40 patients = 87.0% in the TNF2 group). Only a
minority of the patients had second (follow-up) endoscopy due to
disease flares (28 = 13.9% in the TNF1 group, and 6 pa-
tients = 13.0% in the TNF2 group).
The median time from first anti-TNF-alpha antibody treatment
to follow-up colonoscopy was 11 months in the TNF1 group and
25.5 months in the TNF2 group.
Mucosal healing at follow-up colonoscopy
In the TNF1 group, 56 patients (27.7%) had complete mucosal
healing (as defined in the Methods section; Mayo endoscopy score
0 or SES-CD score 0) at follow-up colonoscopy, while 146 patients
(72.3%) had no mucosal healing (Figure 2).
In the TNF2 group, 13 patients (28.3%) patients had complete
mucosal healing at follow-up colonoscopy, while 33 patients
(71.4%) had no mucosal healing at follow-up colonoscopy
(Figure 2).
In the subanalysis of UC patients (n = 96), in the TNF1 group
(n = 82) 23 patients (28.0%) patients had complete mucosal healing
at follow-up colonoscopy, while 59 patients (72.0%) had no
mucosal healing at follow-up colonoscopy (Table S2). In the TNF2
group (n = 14), 5 patients (35.7%) had complete mucosal healing at
follow-up colonoscopy, while 9 patients (64.3%) had no mucosal
healing at follow-up colonoscopy (Table S3).
In the subanalysis of CD patients (n = 152), in the TNF1 group
(n = 120) 33 patients (27.5%) patients had complete mucosal
healing at follow-up colonoscopy, while 87 patients (72.5%) had
no mucosal healing at follow-up colonoscopy (Table S7). In the
TNF2 group (n = 32), 8 patients (25.0%) patients had complete
mucosal healing at follow-up colonoscopy, while 24 patients
Mucosal Healing in IBD
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(75.0%) had no mucosal healing at follow-up colonoscopy (Table
S8).
Univariate analyses reveals serum CRP levels as predictive
factor for mucosal healing at follow-up colonoscopy
In patients with MH, CRP values of follow-up colonoscopy
were significantly lower compared to CRP values at baseline
colonoscopy (median 0.9 mg/dL at baseline vs. 0.3 mg/dL at
follow-up; p = 0.002), while there was no significant difference of
CRP values from baseline to follow-up colonoscopy in patients
without MH (median 1.1 mg/dL at baseline vs. 0.55 mg/dL at
follow-up; p = 0.07; Table 2). Interestingly, combination therapy
with thiopurines and anti-TNF-alpha antibodies had no influence
on mucosal healing status (10 patients with mucosal healing vs. 29
patients without mucosal healing; p = 1.0).
Similar to the TNF1 group, in the TNF2 group CRP values at
follow-up colonoscopy were lower in patients with mucosal healing
compared to baseline values, but not statistically significant (CRP
median 0.6 mg/dL at baseline vs. 0.3 mg/dL at follow-up;
p = 0.16). In patients without MH, CRP values at follow-up were
not significantly different to CRP values at baseline colonoscopy
(CRP median 0.7 mg/dL at baseline vs. 0.8 mg/dL at follow-up;
p = 0.14, Table 3).
At baseline colonoscopy, CRP values were not significantly
different in patients with or without MH in the TNF1 group
(p = 0.95). However, CRP values were significantly lower at follow-
up colonoscopy in patients with MH compared to patients without
MH in the TNF1 group (p = 8.35E-05; Figure 3). Similar to the
TNF1 group, baseline colonoscopy CRP values were not
significantly different in patients with or without MH in the
TNF2 group (p = 0.06). In patients with MH of the TNF2 group,
CRP values at follow-up colonoscopy were significantly lower
compared to patients without MH (p = 0.002; Figure 4).
In the subanalysis of UC patients, CRP values in the TNF1
group at follow-up colonoscopy were significantly lower in patients
with MH compared to patients without MH (CRP median
0.10 mg/dL (MH) vs. 0.50 mg/dL (no MH); p = 0.0002; Figure
S1), while CRP values at baseline colonoscopy were not
significantly different (CRP median 0.6 mg/dL (MH) vs.
1.0 mg/dL (no MH); p = 0.58). In patients with MH, CRP values
of follow-up colonoscopy were significantly lower compared to
CRP values at baseline colonoscopy (CRP median 0.6 mg/dL at
baseline vs. 0.1 mg/dL at follow-up; p = 0.03), while there was no
significant difference of CRP values from baseline to follow-up
colonoscopy in patients without MH (CRP median 1.0 mg/dL at
baseline vs. 0.5 mg/dL at follow-up; p = 0.10). In the TNF2
group, CRP values at follow-up colonoscopy were significantly
lower in patients with mucosal healing compared to patients
without MH (CRP median 0.20 mg/dL (MH) vs. 0.80 mg/dL (no
MH); p = 0.03; Figure S2), while CRP values at baseline
colonoscopy were not significantly different (CRP median
0.55 mg/dL (MH) vs. 0.6 mg/dL (no MH); p = 0.26). In patients
with MH, CRP values of follow-up colonoscopy were significantly
lower compared to CRP values at baseline colonoscopy (CRP
median 0.55 mg/dL at baseline vs. 0.20 mg/dL at follow-up;
p = 0.01); there was no significant difference of CRP values from
baseline to follow-up colonoscopy in patients without MH (CRP
median 0.6 mg/dL at baseline vs. 0.8 mg/dL at follow-up;
p = 0.80).
Figure 1. Study design. Data of 802 patients were available for analysis (75.3% patients with Crohn’s disease and 24.7% patients with ulcerative
colitis). In 554 IBD patients, there was no baseline and/or follow-up colonoscopy available. Accordingly, 248 patients were included in the analysis,
while 202 patients were treated with one anti-TNF antibody between baseline and follow-up colonoscopy (TNF1 group) and 46 patients were treated
with a second anti-TNF antibody after loss of response or intolerance to a first anti-TNF antibody (TNF2 group).
doi:10.1371/journal.pone.0099293.g001
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Table 1. Demographic and clinical characteristics of the study cohorts (n = 248).
TNF1 group TNF2 group
Patients (n = ) 202 46
Median age (yrs) [Range] 38 [18–72] 43.5 [17–73]
Median age at diagnosis (yrs) [Range] 25 [6–63] 26 [7–68]
Median disease duration (yrs) [Range] 10 [0–45] 9.5 [2–44]
Female sex (%) 106 (52.5) 20 (43.5)
Smoker (%) 73 (36.2) 14 (30.4)
Family history of IBD (%) 27 (13.4) 2 (4.3)
Extraintestinal manifestation (%) 80 (39.6) 24 (52.2)
Crohn’s disease (%) 120 (59.4) 32 (69.6)
Ulcerative colitis (%) 82 (40.6) 14 (30.4)
Mean CRP-value at baseline colonoscopy (mg/dL) [Range] 2.409 [0.1–33.8] 2.425 [0.1–15.4]
Mean CRP-value at follow-up colonoscopy (mg/dL) [Range] 1.341 [0.1–23.1] 1.351 [0.1–10.1]
Mean WBC at baseline colonoscopy (G/L) [Range] 9.263 [2.3–23.1] 9.697 [4.4;23.9]
Mean WBC at follow-up colonoscopy (G/L) [Range] 7.493 [1.6;17.3] 8.389 [2.7;19.5]
Thiopurine treatment ever (%) 172 (85.1) 44 (95.7)
Median thiopurine treatment duration (months) [Range] 40 [0;211] 60.5 [43;237]
Infliximab treated patients (%) 188 (93.1) 4 (8.7)
Adalimumab treated patients (%) 14 (6.9) 42 (91.3)
Anti-TNF-alpha antibody and thiopurine treated patients at follow-up (%) 39 (19.3) 5 (10.9)
Median duration infliximab treatment (months) [Range] 11 [0–70] 18 [1–39]
Median duration adalimumab treatment (months) [Range] 6 [1–41] 10.5 [0–44]
Median time to first anti-TNF-alpha antibody treatment (years) [Range] 7 [0–42] 7 [0–39]
Median time from baseline to follow-up colonoscopy (months) [Range] 19 [0–123] 39.5 [1–104]
Median time from first to second anti-TNF-alpha antibody treatment (months) [Range] n/a 7.5 [0–68]
Patients with surgery until follow-up (%) 34 (16.8) 10 (23.8)
Patients hospitalized until follow-up (%) 57 (28.2) 18 (39.1)
Median follow-up (months) [Range] 63 [3–127] 64.5 [9–126]
doi:10.1371/journal.pone.0099293.t001
Figure 2. Rates of mucosal healing in both groups. In the TNF1 group, 146 patients (72.3%) had no MH, while 56 patients (27.7%) had MH. In
the TNF2 group, 13 patients (28.6%) patients had MH, while 33 patients (71.4%) had no MH at follow-up colonoscopy.
doi:10.1371/journal.pone.0099293.g002
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In the subanalysis of CD patients, CRP values in the TNF1
group at follow-up colonoscopy were significantly lower in patients
with MH compared to patients without MH (CRP median
0.40 mg/dL (MH) vs. 0.60 mg/dL (no MH); p = 0.01; Figure S3),
while CRP values at baseline colonoscopy were not significantly
different (CRP median 1.5 mg/dL (MH) vs. 1.15 mg/dL (no
MH); p = 0.57). In patients with MH, CRP values of follow-up
colonoscopy were significantly lower compared to CRP values at
baseline colonoscopy (median 1.5 mg/dL at baseline vs. 0.4 mg/
dL at follow-up; p = 0.02), while there was no significant difference
of CRP values from baseline to follow-up colonoscopy in patients
without MH (median 1.15 mg/dL at baseline vs. 0.6 mg/dL at
follow-up; p = 0.23). In the TNF2 group, CRP values at follow-up
colonoscopy were significantly lower in patients with MH
compared to patients without MH (CRP median 0.60 mg/dL
(MH) vs. 0.70 mg/dL (no MH); p = 0.01; Figure S4), while CRP
values at baseline colonoscopy were not significantly different
(CRP median 0.6 mg/dL (MH) vs. 2.3 mg/dL (no MH); p = 0.08).
However, in patients with MH, CRP values of follow-up
colonoscopy were not significantly lower compared to CRP values
at baseline colonoscopy (median 0.6 mg/dL at baseline vs.
0.6 mg/dL at follow-up; p = 0.24); there was also no significant
difference of CRP values from baseline to follow-up colonoscopy
in patients without MH (median 2.3 mg/dL at baseline vs.
0.7 mg/dL at follow-up; p = 0.16).
Mulitvariate analyses reveals serum CRP levels as
predictive factor for mucosal healing at follow-up
colonoscopy
Multivariate analysis confirmed CRP at follow-up colonoscopy
as predictive factor for MH (p = 0.01) in the TNF1 group, while
CRP at follow-up colonoscopy was not predictive for MH in the
TNF2 group (p = 0.11, Tables 4 and 5).
Table 2. Demographic and clinical characteristics of the TNF1 group (n = 202) regarding MH.
MH No MH p-value OR [95%CI]
Patients (n = ) 56 (27.7) 146 (72.3) N/A N/A
Median age (yrs) [Range] 38 [19;67] 37.5 [18;72] 0.961 1.001 [0.978;1.023]
Median age at diagnosis (yrs) [Range] 27.5 [14;48] 25 [6;63] 0.665 1.006 [0.980;1.033]
Median disease duration (yrs) [Range] 9.5 [0;33] 10 [0;45] 0.719 0.994 [0.961;1.027]
Female sex (%) 31 (55.4) 75 (51.4) 0.644 0.864 [0.465;1.605]
Smoker (%) 24 (42.9) 49 (33.6) 0.361 0.875 [0.658;1.165]
Family history of IBD (%) 3 (5.4) 24 (16.4) 0.048 3.556 [1.012;12.493]
Extraintestinal manifestation (%) 23 (41.1) 57 (39) 0.872 0.872 [0.428;1.778]
Diagnosis Crohn’s disease/Ulcerative colitis 33/23 87/59 0.932 0.973 [0.520;1.821]
Mean (median) CRP-value at baseline
colonoscopy (mg/dL) [Range]
2.441 (0.9) [0.1;14.8] 2.398 (1.1) [0.1;33.8] 0.948 0.997 [0.910;1.093]
Mean (median) CRP-value at follow-up
colonoscopy (mg/dL) [Range]
0.583 (0.3) [0.1;4.3] 1.641 (0.550) [0.1;23.1] 0.040 1.705 [1.180;2.464]
Mean (median) WBC at baseline
colonoscopy (G/L) [Range]
9.234 (8.5) [2.3;19.7] 9.274 (8.5) [3.5;23.1] 0.951 1.003 [0.916;1.098]
Mean (median) WBC at follow-up
colonoscopy (G/L) [Range]
6.531(6.3) [1.6;14.6] 7.882 (7.700) [3.3;17.3] 0.02 1.250 [1.084;1.442]
Thiopurine treatment ever (%) 46 (82.1) 126 (86.3) 0.906 0.906 [0.176;4.649]
Median thiopurine treatment duration
(months) [Range]
24 [4;104] 44.5 [0;211] 0.261 1.013 [0.990;1.037]
Infliximab treated patients (%) 53 (94.6) 135 (92.5) 0.7615 N/A
Adalimumab treated patients (%) 3 (5.4) 11 (7.5) 0.7615 N/A
Anti-TNF-alpha antibody and thiopurine
treated patients at follow-up (%)
10 (17.9) 29 (19.9) 1.000 N/A
Median duration infliximab treatment
(months) [Range]
12.5 [0;69] 10 [0;70] 0.4191 0.992 [0.971;1.012]
Median duration adalimumab treatment
(months) [Range]
12 [0;69] 10 [0;70] 0.727 0.996 [0.975;1.018]
Median thiopurine treatment duration
(months) [Range]
22.5 [1;41] 6 [1;25] 0.078 0.883 [0.769;1.014]
Median time to first anti-TNF-alpha
antibody treatment (years) [Range]
6 [0;30] 7 [0;42] 0.835 0.996 [0.960;1.033]
Median time from baseline to follow-up
colonoscopy (months) [Range]
19.5 [0;106] 19 [0;123] 0.853 0.999 [0.984;1.013]
Patients with surgery until follow-up (%) 3 (5.4) 31 (21.2) 0.006 N/A
Patients hospitalized until follow-up (%) 10 (17.9) 47 (32.2) 0.054 N/A
Median follow-up (months) [Range] 70 [22;127] 60 [3;125] 0.141 0.991 [0.980;1.003]
doi:10.1371/journal.pone.0099293.t002
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In the subanalysis of UC patients, CRP at follow-up colonos-
copy was not predictive for MH in the TNF1 group (p = 0.06) and
the TNF2 group (p = 0.39) (Tables S4 and S5). In the subanalysis
of CD patients, CRP at follow-up colonoscopy was also not
predictive for MH in the TNF1 group (p = 0.08) and the TNF2
group (p = 0.28) (Tables S9 and S10).
Rate of hospitalization and surgery
Ten patients with MH and 47 patients without MH in the
TNF1 group (p = 0.054) and 2 patients with MH and 16 patients
without MH in the TNF2 group (p = 0.05) were hospitalized due
to IBD (Tables 2 and 3).
Overall, 3 patients with MH and 31 patients without MH in the
TNF1 group (p = 0.006) and no patient with MH and 10 patients
without MH (p = 0.04) had surgery until follow-up in the TNF2
group (Tables 2 and 3). Accordingly, Kaplan-Mayer estimation
revealed significantly lower need for surgery in patients with MH
compared to patients without MH in both groups (Figures 5 and
6).
In the subanalysis of UC patients, 1 patients with MH and 21
patients without MH in the TNF1 group (p = 0.005) and no
patient with MH and 5 patients without MH in the TNF2 group
(p = 0.08) were hospitalized due to IBD. Overall, no patient with
MH and 7 patients without MH in the TNF1 group (p = 0.18) and
Table 3. Demographic and clinical characteristics of the TNF2 group (n = 46) regarding MH.
MH No MH p-value OR [95%CI]
Patients (n = ) 13 (28.6) 33 (71.4) N/A N/A
Median age (yrs) [Range] 44 [26;73] 42 [17;69] 0.277 0.974 [0.929;1.021]
Median age at diagnosis (yrs) [Range] 33 [7;68] 25 [10;55] 0.142 0.965 [0.921;1.012]
Median disease duration (yrs) [Range] 8 [3;39] 12 [2;44] 0.607 1.018 [0.950;1.091]
Female sex (%) 7 (53.8) 13 (39.4) 0.376 0.557 [0.153;2.034]
Smoker (%) 4 (30.8) 10 (30.3) 0.530 0.763 [0.327;1.777]
Family history of IBD (%) 1 (7.7) 1 (3.0) 0.477 0.355 [0.02;6.172]
Extraintestinal manifestation (%) 3 (23.1) 21 (63.6) 0.035 5.091 [1.12;23.142]
Diagnosis Crohn’s disease/Ulcerative colitis 8/5 24/9 0.460 0.60 [0.155;2.325]
Mean (median) CRP-value at baseline
colonoscopy (mg/dL) [Range]
1.167 (0.6) [0.1;4.9] 2.902 (0.67) [0.1;15.4] 0.212 1.329 [0.850;2.079]
Mean (median) CRP-value at follow-up
colonoscopy (mg/dL) [Range]
0.380 (0.300) [0.1;0.8] 1.645 (0.8) [0.1;10.1] 0.003 0.31 [0.144;0.661]
Mean (median) WBC at baseline
colonoscopy (G/L) [Range]
9.144 (8.1) [6.8;12.6] 10.064 (9.1) [4.4;23.9] 0.581 1.075 [0.831;1.390]
Mean (median) WBC at follow-up
colonoscopy (G/L) [Range]
8.265 (7.0) [4;19.3] 8.430 (7.70) [2.7;19.5] 0.904 1.011 [0.849;1.204]
Thiopurine treatment ever (%) 13 (100) 31 (93.9) 1.000 N/A
Median thiopurine treatment duration
(months) [Range]
75 [75;75] 46 [43;237] 0.725 1.006 [0.971;1.043]
Infliximab after adalimumab treated
patients (%)
1 (7.7) 3 (9.1) 1.000 N/A
Adalimumab after infliximab treated
patients (%)
12 (92.3) 30 (91.9) 1.000 N/A
Anti-TNF-alpha antibody and thiopurine
treated patients at follow-up (%)
1 (7.7) 4 (12.1) 1.000 N/A
Median duration infliximab treatment
(months) [Range]
17 [9;95] 29 [0;68] 0.985 1.000 [0.969;1.032]
Median duration adalimumab treatment
(months) [Range]
17 [17;17] 19 [1;39] 0.865 1.015 [0.855;1.205]
Median thiopurine treatment duration
(months) [Range]
9.5 [2;44] 13 [0;42] 0.458 0.981 [0.931;1.033]
Median time to first anti-TNF-alpha antibody
treatment (years) [Range]
5 [0;37] 8 [0;39] 0.625 1.017 [0.950;1.089]
Median time from baseline to follow-up
colonoscopy (months) [Range]
45 [14;90] 33 [1;104] 0.332 0.988 [0.964;1.012]
Median time from first to second anti-TNF-
alpha antibody treatment (months) [Range]
5 [1;68] 10 [0;56] 0.576 1.013 [0.968;1.06]
Patients with surgery until follow-up (%) 0 (0) 10 (30.3) 0.042 N/A
Patients hospitalized until follow-up (%) 2 (15.4) 16 (48.5) 0.049 N/A
Median follow-up (months) [Range] 77 [14;123] 58 [9;126] 0.461 0.993 [0.973;1.012]
doi:10.1371/journal.pone.0099293.t003
Mucosal Healing in IBD
PLOS ONE | www.plosone.org 6 June 2014 | Volume 9 | Issue 6 | e99293
no patient with MH and 3 patients without MH (p = 0.25) had
surgery until follow-up in the TNF2 group (Tables S2 and S3).
In the subanalysis of CD patients, 9 patients with MH and 26
patients without MH in the TNF1 group (p = 0.82) and 2 patients
with MH and 11 patients without MH in the TNF2 group
(p = 0.42) were hospitalized due to IBD. Overall, 3 patients with
MH and 24 patients without MH in the TNF1 group (p = 0.049)
and no patient with MH and 7 patients without MH (p = 0.14) had
surgery until follow-up in the TNF2 group (Tables S7 and S8).
Figure 3. CRP values at follow-up colonoscopy (TNF1 group). At follow-up colonoscopy, CRP values were significantly lower in patients with
MH compared to patients without MH (*p = 8.34E-05).
doi:10.1371/journal.pone.0099293.g003
Figure 4. CRP values at follow-up colonoscopy (TNF2 group). At follow-up colonoscopy, there was a trend for lower CRP in patients with MH
compared to patients without MH (*p = 0.002).
doi:10.1371/journal.pone.0099293.g004
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Kaplan-Mayer estimation revealed significantly lower need for
surgery in patients with MH compared to patients without MH
only in the TNF1 group of CD patients (Figures S5, S6, S7, S8).
Discussion
Mucosal healing (MH) in patients with IBD is an important
treatment goal, leading to better long-term remission rates, better
quality of life, lower need for hospitalisation and surgeries, and
lower rates of colorectal cancer [9,12,13,14]. MH can be achieved
with various treatment strategies including immunosuppressive
therapies such as methotrexate or thiopurines and anti-TNF-alpha
antibodies [8,15,16,17,18]. Former studies have demonstrated that
corticosteroids are not suitable for maintenance of mucosal healing
[19], and combination therapy with thiopurines and anti-TNF-
alpha antibodies is superior compared to thiopurine monotherapy
in CD regarding remission rates and MH [20]. Emerging data
indicate that early use of anti-TNF-alpha antibodies lead to better
long-term outcome in IBD patients by preventing mucosal damage
[8,10,13,21]. However, results from prospective large-scale studies
are still very limited.
In our study, we found a MH prevalence of 27.7% in patients
who were treated with one anti-TNF-alpha antibody (TNF1
group) and 28.3% in a second cohort which included patients who
were switched to another anti-TNF-alpha antibody (TNF2 group)
due to intolerance or loss of response. The MH rates in our cohort
were somewhat lower than that of previously published studies
which is related to the strict definition of MH in our study which
required complete endoscopic MH (Mayo endoscopic subscore 0
for UC patients or SES-CD score 0 for CD patients, respectively).
Of note, our study comprises a large cohort with a long follow-up
time (median overall follow-up time: TNF1 group 63 months,
TNF2 group 64.5 months) compared to most other clinical studies
which have much shorter follow-up times. Another new finding of
our study is that switch from a first anti-TNF-alpha antibody to a
second anti-TNF-alpha antibody had no significant impact on
MH rates, independently from the reason for switch. However,
since most of our patients were switched due to allergic reaction or
intolerance, MH rates might be lower when switch is done due to
loss of response. Similar to recent studies, which demonstrated a
lower need for surgeries and hospitalization in patients who have
MH [9,14], we confirmed these findings. Regarding predictive
factors for MH, CRP values in the TNF1 group and in the TNF2
Table 4. Multivariate analysis for outcome MH in the TNF1 group (n = 202).
p-value OR [95%CI]
CRP-value at baseline colonoscopy 0.398 1.080 [0.904;1.290]
CRP-value at follow-up colonoscopy 0.012 1.687 [1.124;2.533]
WBC at baseline colonoscopy 0.685 0.976 [0.870;1.096]
WBC at follow-up colonoscopy 0.026 1.187 [1.021;1.380]
Age at diagnosis 0.869 0.901 [0.262;3.098]
Age 0.854 1.123 [0.326;3.865]
Gender 0.174 0.602 [0.289;1.251]
Smoker 0.428 0.871 [0.620;1.225]
Duration anti-TNF-alpha antibody treatment 0.691 0.992 [0.951;1.034]
Time to first anti-TNF-alpha antibody treatment 0.102 1.176 [0.968;1.429]
Time from baseline to follow-up colonoscopy 0.893 1.002 [0.967;1.039]
doi:10.1371/journal.pone.0099293.t004
Table 5. Multivariate analysis for outcome MH in the TNF2 group (n = 46).
p-value OR [95%CI]
CRP-value at baseline colonoscopy 0.197 1.976 [0.702;5.561]
CRP-value at follow-up colonoscopy 0.106 3.640 [0.761;17.415]
WBC at baseline colonoscopy 0.350 1.149 [0.859;1.538]
WBC at follow-up colonoscopy 0.719 0.957 [0.753;1.252]
Age at diagnosis 0.556 0.825 [0.436;1.563]
Age 0.527 1.228 [0.650;2.321]
Gender 0.201 0.137 [0.007;2.877]
Smoker 0.135 0.419 [0.134;1.312]
Duration anti-TNF-alpha antibody treatment 0.857 0.993 [0.924;1.068]
Time to first anti-TNF-alpha antibody treatment 0.231 0.600 [0.259;1.386]
Time from baseline to follow-up colonoscopy 0.201 1.098 [0.951;1.267]
Time from first to second anti-TNF-alpha antibody treatment 0.639 0.973 [0.866;1.092]
doi:10.1371/journal.pone.0099293.t005
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group at follow-up colonoscopy were significantly lower in patients
with MH, when compared to patients without MH. Multivariate
analysis confirmed CRP as a predictive marker in the TNF1
group, while smoking was negatively associated with MH in this
group.
When dividing our patient cohort regarding their disease entity
(CD and UC), the MH rates remain similar to the overall cohorts
(CD: TNF1 group 27.5%, TNF2 group 25.0%; UC: TNF1 group
28.0%, TNF2 group 35.7%). In univariate analyses, both in CD
and UC patients, low CRP levels at follow-up were associated with
MH. However, multivariate analyses could not confirm CRP at
follow-up as a predictive marker in both groups. This might be
explained by the relative small sample size, especially in the TNF2
groups.
Interestingly, a recent study also demonstrated normalisation of
CRP as a strong predictor of efficacy and mucosal healing during
the first year of adalimumab therapy in CD [18]. In this study,
logistic regression analysis revealed normalisation of CRP (defined
as CRP,10 mg/L) at week 12 after initiation of adalimumab
therapy as a predictive factor for MH (p,0.001). Another study
also showed that CRP correlated with MH (p = 0.033) in CD
patients treated with infliximab [22].
Figure 5. Kaplan-Mayer estimate for surgery-free time intervals in the TNF1 group over the follow-up time. During the follow-up time,
3 patients with MH underwent surgery as compared to 31 patients without MH patients (logrank p = 0.01).
doi:10.1371/journal.pone.0099293.g005
Figure 6. Kaplan-Mayer estimate for surgery-free time intervals in the TNF2 group over the follow-up time. During the follow-up time,
no patient with MH underwent surgery as compared to 10 patients without MH (logrank p = 0.03).
doi:10.1371/journal.pone.0099293.g006
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The anti-TNF-alpha antibodies infliximab and adalimumab
have the potential to induce and maintain MH in IBD [13,17,23].
Moreover, there is evidence that early infliximab-induced MH is
associated with a better long-term outcome and a lower need for
major abdominal surgeries in CD and UC [8,9,24]. A recent
retrospective analysis demonstrated that infliximab induced MH
in 45% of CD patients 3 months after start of inflixmab which was
highly predictive for MH after 12 months [25]. One possible
mechanism by which infliximab induces mucosal healing in UC is
down-regulation of basic fibroblast growth factor/syndecan 1 [26].
Another study revealed a significant induction of regulatory
macrophages in patients with mucosal healing after treatment with
infliximab which was more pronounced in patients receiving
infliximab/azathioprine combination treatment [27]. This might
be an explanation for the better outcome of this combination
treatment regime in clinical practice and as demonstrated in the
SONIC trial [20]. However, in our study combination therapy
with anti-TNF-alpha antibody and thiopurines was not associated
with a higher rate of MH. Other important mechanisms by which
anti-TNF-alpha antibodies may promote MH are downregulation
of proinflammatory cytokines/chemokines [28], matrix-metallo-
proteinases, tissue inhibitors of metalloproteinases [29] and
apoptosis/necroptosis [30].
One may speculate if early start of anti-TNF-alpha antibody
treatment could have improved the rates of MH in our study cohort,
since most of the patients in our study underwent step-up strategies
and were treated with an anti-TNF-alpha antibody only 7 years
(median) after the first diagnosis of IBD. In the large anti-TNF-
alpha antibody landmark trials, MH rates are varying with the
different time points of assessment. In CD patients, infliximab
induced MH rates ranging from 29% to 45% [20,31] and 27% with
adalimumab [32]. In studies with UC patients, MH rates are higher
and ranged from 47% with adalimumab [23] and 60% with
infliximab [24]. However, in contrast to these anti-TNF-alpha
antibody studies, in which patients have routine colonoscopy after a
defined time point after initiation of anti-TNF-alpha antibody
treatment, in clinical practice patients without clinical symptoms are
often not willing to undergo colonoscopy. Accordingly, data from
these patients are missing and in a real life situation there might be
higher rates of MH in anti-TNF-alpha antibody-treated patients
who have no colonoscopy after start of anti-TNF-alpha antibody
therapy, since clinical activity was obviously low and there was no
need for routine diagnostic colonoscopy.
There are some limitations of our study, mostly due to its
retrospective nature: first, there were limited data on clinical scores
like CDAI/CAI. However, there is evidence that CDAI and CAI
as subjective scoring systems are not suitable to determine MH
[33]. Moreover, only in a few patients neutrophil-derived fecal
stool markers like calprotectin were available to be correlated with
MH. Second, time periods between baseline and follow-up
colonoscopy were varying (see table 1). However, there was no
significant difference in the time interval between baseline and
follow-up colonoscopy among patients with and without MH. In
the majority of our patients (88%), the main reason for second
(follow-up) colonoscopy was routine control of ongoing anti-TNF-
alpha antibody therapy, and only few colonoscopies were
performed due to flare of the disease (12%). Accordingly, CRP
values at baseline colonoscopy were not significantly different in
both groups, which suggest similar clinical disease activity.
As noted above, colonoscopy as an invasive procedure has a low
acceptance rate in asymptomatic IBD patients. Other non-invasive
diagnostic modalities for the assessment of MH like fecal
calprotectin [34,35], lactoferrin [35] or combination of fecal
calprotectin and clinical activity scores (e.g. Harvey-Bradshaw
index) [36] and radiological techniques (e.g. MR enteroclysis [37])
may serve as additional or alternative markers of MH in the near
future. However, despite the presence of complete MH, histolog-
ical findings which predict disease relapse like basal plasma cell
infiltration in UC patients [38], are valuable markers and should
be additionally taken into account when monitoring IBD patients.
In summary, in nearly 30% of IBD patients treated with anti-
TNF-alpha antibodies we observed complete MH. Switch from
one anti-TNF-alpha antibody to a second anti-TNF-alpha
antibody had no significant impact on MH rates in our study.
We confirmed former findings that the need for surgeries and
hospitalisation was lower in patients with MH than in patients
without MH. After initiation of an anti-TNF-alpha antibody
therapy, low CRP values at follow-up colonoscopy compared to a
baseline colonoscopy were associated with MH. Therefore, in
clinical practice the CRP value seems to be an easy-to-use marker
for MH in IBD patients. Further prospective studies comparing
step-up versus early interventional top-down strategies and defined
colonoscopy intervals after the start of anti-TNF-alpha antibody
treatment are warranted to assess their value for complete MH
and long term outcome of these patients.
Supporting Information
Figure S1 CRP values of UC patients at follow-up
colonoscopy (TNF1 group). At follow-up colonoscopy, CRP
values were significantly lower in patients with MH compared to
patients without MH (*p = 0.0002).
(TIF)
Figure S2 CRP values of UC patients at follow-up
colonoscopy (TNF2 group). At follow-up colonoscopy, CRP
values were significantly lower in patients with MH compared to
patients without MH (*p = 0.03).
(TIF)
Figure S3 CRP values of CD patients at follow-up
colonoscopy (TNF1 group). At follow-up colonoscopy, CRP
values were significantly lower in patients with MH compared to
patients without MH (*p = 0.01).
(TIF)
Figure S4 CRP values of CD patients at follow-up
colonoscopy (TNF2 group). At follow-up colonoscopy, CRP
values were significantly lower in patients with MH compared to
patients without MH (*p = 0.01).
(TIF)
Figure S5 Kaplan-Mayer estimate for surgery-free time
intervals in UC patients (TNF1 group) during the follow-
up time. During the follow-up time, no patient with MH
underwent surgery as compared to 7 patients without MH patients
(logrank p = 0.09).
(TIF)
Figure S6 Kaplan-Mayer estimate for surgery-free time
intervals in UC patients (TNF2 group) during the follow-
up time. During the follow-up time, no patient with MH
underwent surgery as compared to 3 patients without MH patients
(logrank p = 0.17).
(TIF)
Figure S7 Kaplan-Mayer estimate for surgery-free time
intervals in CD patients (TNF1 group) during the follow-
up time. During the follow-up time, 3 patients with MH
underwent surgery as compared to 24 patients without MH
patients (logrank p = 0.04).
(TIF)
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Figure S8 Kaplan-Mayer estimate for surgery-free time
intervals in CD patients (TNF2 group) during the follow-
up time. During the follow-up time, no patient with MH
underwent surgery as compared to 7 patients without MH patients
(logrank p = 0.09).
(TIF)
Table S1 Demographic and clinical characteristics of
the UC study cohort (n = 96).
(DOC)
Table S2 Demographic and clinical characteristics of
the UC TNF1 group (n = 82) regarding MH.
(DOC)
Table S3 Demographic and clinical characteristics of
the UC TNF2 group (n = 14) regarding MH.
(DOC)
Table S4 Multivariate analysis for outcome MH in the
UC TNF1 group.
(DOC)
Table S5 Multivariate analysis for outcome MH in the
UC TNF2 group.
(DOC)
Table S6 Demographic and clinical characteristics of
the CD study cohort (n = 152).
(DOC)
Table S7 Demographic and clinical characteristics of
the CD TNF1 group (n = 120) regarding MH.
(DOC)
Table S8 Demographic and clinical characteristics of
the CD TNF2 group (n = 32) regarding MH.
(DOC)
Table S9 Multivariate analysis for outcome MH in the
MC TNF1 group.
(DOC)
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